Detailed information for compound 1969984

Basic information

Technical information
  • Name: Unnamed compound
  • MW: 404.468 | Formula: C21H24N8O
  • H donors: 3 H acceptors: 6 LogP: 2.25 Rotable bonds: 6
    Rule of 5 violations (Lipinski): 1
  • SMILES: C[C@@H](CNc1ccc(nn1)Nc1ncc2c(n1)n(C1CCCC1)c1c2ccnc1)O
  • InChi: 1S/C21H24N8O/c1-13(30)10-23-18-6-7-19(28-27-18)25-21-24-11-16-15-8-9-22-12-17(15)29(20(16)26-21)14-4-2-3-5-14/h6-9,11-14,30H,2-5,10H2,1H3,(H,23,27)(H,24,25,26,28)/t13-/m0/s1
  • InChiKey: QCXMOVSRDNYGQN-ZDUSSCGKSA-N  


Substructure search Similarity search

Network

Hover on a compound node to display the structore

Synonyms

No synonyms found for this compound

Targets

Known targets for this compound

Species Target name Source Bibliographic reference
Homo sapiens cyclin-dependent kinase 4 Starlite/ChEMBL No references
Homo sapiens cyclin-dependent kinase 6 Starlite/ChEMBL No references

Predicted pathogen targets for this compound

By orthology
Species Potential target Known druggable target/s Ortholog Group
Schistosoma japonicum ko:K02091 cyclin-dependent kinase 6, putative Get druggable targets OG5_133618 All targets in OG5_133618
Echinococcus multilocularis cyclin dependent kinase 6 Get druggable targets OG5_133618 All targets in OG5_133618
Echinococcus granulosus cyclin dependent kinase 6 Get druggable targets OG5_133618 All targets in OG5_133618
Schistosoma mansoni serine/threonine protein kinase Get druggable targets OG5_133618 All targets in OG5_133618
By sequence similarity to non orthologous known druggable targets
Species Potential target Known druggable target Length Alignment span Identity
Trypanosoma brucei mitogen-activated protein kinase 5 cyclin-dependent kinase 6 326 aa 314 aa 31.2 %
Trypanosoma brucei mitogen-activated protein kinase 5 cyclin-dependent kinase 4 303 aa 312 aa 29.8 %
Obtained from network model

Ranking Plot

Putative Targets List

Species Potential target Raw Global Species
Schistosoma mansoni serine/threonine-protein kinase 0.0148 0.5363 0.5806
Trypanosoma brucei rac serine-threonine kinase, putative 0.0215 1 0.5
Trypanosoma cruzi Protein kinase B 0.0148 0.5363 1
Echinococcus granulosus sodium:potassium dependent atpase beta subunit 0.0132 0.4274 0.4628
Echinococcus multilocularis nervana 2 0.0132 0.4274 0.4628
Trichomonas vaginalis AGC family protein kinase 0.0215 1 1
Echinococcus multilocularis nervana 2 0.0132 0.4274 0.4628
Entamoeba histolytica PH domain containing protein kinase, putative 0.0148 0.5363 0.5363
Echinococcus granulosus Glutaredoxin protein 5 0.0132 0.4274 0.4628
Trichomonas vaginalis AGC family protein kinase 0.0215 1 1
Trichomonas vaginalis AGC family protein kinase 0.0083 0.091 0.091
Echinococcus multilocularis serine threonine protein kinase nrc serine threonine protein kinase gad 0.0135 0.4453 0.4821
Echinococcus multilocularis rac serine:threonine kinase 0.0148 0.5363 0.5806
Schistosoma mansoni serine/threonine-protein kinase 0.0148 0.5363 0.5806
Trichomonas vaginalis AGC family protein kinase 0.0215 1 1
Echinococcus multilocularis Glutaredoxin protein 5 0.0132 0.4274 0.4628
Entamoeba histolytica protein kinase 2, putative 0.0135 0.4453 0.4453
Trichomonas vaginalis AGC family protein kinase 0.0215 1 1
Entamoeba histolytica protein kinase, putative 0.0215 1 1
Loa Loa (eye worm) AGC/AKT protein kinase 0.0215 1 1
Trichomonas vaginalis AGC family protein kinase 0.0215 1 1
Toxoplasma gondii AGC kinase 0.0202 0.909 0.5
Echinococcus granulosus nervana 2 0.0132 0.4274 0.4628
Plasmodium falciparum RAC-beta serine/threonine protein kinase 0.0135 0.4453 0.5
Trichomonas vaginalis AGC family protein kinase 0.0215 1 1
Entamoeba histolytica protein kinase, putative 0.0202 0.909 0.909
Echinococcus granulosus cyclin dependent kinase 6 0.0204 0.9236 1
Echinococcus granulosus serine/threonine protein kinase 0.0148 0.5363 0.5806
Schistosoma mansoni serine/threonine protein kinase 0.0204 0.9236 1
Plasmodium vivax rac-beta serine/threonine protein kinase, putative 0.0135 0.4453 0.5
Loa Loa (eye worm) AGC/RSK/P70 protein kinase 0.0202 0.909 0.909
Entamoeba histolytica protein kinase, putative 0.0215 1 1
Entamoeba histolytica PH domain containing protein kinase, putative 0.0148 0.5363 0.5363
Echinococcus multilocularis sodium:potassium dependent atpase beta subunit 0.0132 0.4274 0.4628
Echinococcus granulosus calcium:calmodulin dependent protein kinase 0.0135 0.4453 0.4821
Echinococcus multilocularis cyclin dependent kinase 6 0.0204 0.9236 1
Echinococcus granulosus serine threonine protein kinase nrc 0.0135 0.4453 0.4821
Trypanosoma cruzi rac serine-threonine kinase, putative 0.0148 0.5363 1
Echinococcus granulosus nervana 2 0.0132 0.4274 0.4628
Brugia malayi p70 ribosomal S6 kinase beta 0.0202 0.909 0.909
Giardia lamblia Kinase, AGC PKA 0.0135 0.4453 0.5
Trichomonas vaginalis AGC family protein kinase 0.0215 1 1

Activities

Activity type Activity value Assay description Source Reference
IC50 (binding) = 4.6 nM BindingDB_Patents: In Vitro Assay. The Cdk4 and Cdk6 inhibitory activity of the compounds is measured with a kinase inhibition assay using recombinant Cdk4/CyclinD1 or Cdk6/CyclinD3 protein complexes. The protein substrate used in the assay is the retinoblastoma protein (Rb). The kinase reactions are carried out in a 96-well filter plate (MSDV N6B50, Millipore). Compounds are serially diluted in kinase buffer (20 mM Tris-HCl, pH 7.4, 50 mM NaCl, 1 mM DTT, 1 mg/ml BSA) and added to the reaction mixture containing 2.5 ng/ml Cdk4/CyclinD1 or Cdk6/CyclinD3, 25 µM ATP, 10 µCi/ml [33P]-ATP, 0.1 µg/ml Rb in the kinase buffer. The mixture is incubated at room temperature for 1 hour and the proteins precipitated with an equal volume of 20% TCA. The plates are washed with 10% TCA according to the manufacturer's instruction and dried at room temperature. The amount of the phosphorylated Rb is determined with a TopCount (PerkinElmer). ChEMBL. No reference
IC50 (binding) = 5.9 nM BindingDB_Patents: In Vitro Assay. The Cdk4 and Cdk6 inhibitory activity of the compounds is measured with a kinase inhibition assay using recombinant Cdk4/CyclinD1 or Cdk6/CyclinD3 protein complexes. The protein substrate used in the assay is the retinoblastoma protein (Rb). The kinase reactions are carried out in a 96-well filter plate (MSDV N6B50, Millipore). Compounds are serially diluted in kinase buffer (20 mM Tris-HCl, pH 7.4, 50 mM NaCl, 1 mM DTT, 1 mg/ml BSA) and added to the reaction mixture containing 2.5 ng/ml Cdk4/CyclinD1 or Cdk6/CyclinD3, 25 µM ATP, 10 µCi/ml [33P]-ATP, 0.1 µg/ml Rb in the kinase buffer. The mixture is incubated at room temperature for 1 hour and the proteins precipitated with an equal volume of 20% TCA. The plates are washed with 10% TCA according to the manufacturer's instruction and dried at room temperature. The amount of the phosphorylated Rb is determined with a TopCount (PerkinElmer). ChEMBL. No reference
IC50 (binding) = 16 nM BindingDB_Patents: In Vitro Assay. The Cdk4 and Cdk6 inhibitory activity of the compounds is measured with a kinase inhibition assay using recombinant Cdk4/CyclinD1 or Cdk6/CyclinD3 protein complexes. The protein substrate used in the assay is the retinoblastoma protein (Rb). The kinase reactions are carried out in a 96-well filter plate (MSDV N6B50, Millipore). Compounds are serially diluted in kinase buffer (20 mM Tris-HCl, pH 7.4, 50 mM NaCl, 1 mM DTT, 1 mg/ml BSA) and added to the reaction mixture containing 2.5 ng/ml Cdk4/CyclinD1 or Cdk6/CyclinD3, 25 uM ATP, 10 uCi/ml [33P]-ATP, 0.1 ug/ml Rb in the kinase buffer. The mixture is incubated at room temperature for 1 hour and the proteins precipitated with an equal volume of 20% TCA. The plates are washed with 10% TCA according to the manufacturer's instruction and dried at room temperature. The amount of the phosphorylated Rb is determined with a TopCount (PerkinElmer). ChEMBL. No reference
IC50 (binding) = 26 nM BindingDB_Patents: In Vitro Assay. The Cdk4 and Cdk6 inhibitory activity of the compounds is measured with a kinase inhibition assay using recombinant Cdk4/CyclinD1 or Cdk6/CyclinD3 protein complexes. The protein substrate used in the assay is the retinoblastoma protein (Rb). The kinase reactions are carried out in a 96-well filter plate (MSDV N6B50, Millipore). Compounds are serially diluted in kinase buffer (20 mM Tris-HCl, pH 7.4, 50 mM NaCl, 1 mM DTT, 1 mg/ml BSA) and added to the reaction mixture containing 2.5 ng/ml Cdk4/CyclinD1 or Cdk6/CyclinD3, 25 uM ATP, 10 uCi/ml [33P]-ATP, 0.1 ug/ml Rb in the kinase buffer. The mixture is incubated at room temperature for 1 hour and the proteins precipitated with an equal volume of 20% TCA. The plates are washed with 10% TCA according to the manufacturer's instruction and dried at room temperature. The amount of the phosphorylated Rb is determined with a TopCount (PerkinElmer). ChEMBL. No reference

Phenotypes

Whole-cell/tissue/organism interactions

We have no records of whole-cell/tissue assays done with this compound What does this mean?

Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.

Annotated phenotypes:

We have no manually annotated phenotypes for this drug. What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
 
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.

External resources for this compound

Bibliographic References

No literature references available for this target.

If you have references for this compound, please enter them in a user comment (below) or Contact us.